GLP-1RAs, originally developed for glycemic control, have shown neuroprotective properties in many preclinical studies
Animal studies are essential for advancing our understanding of AD, identifying potential drug targets, and testing experimental treatments
Patients begin by scheduling a medical weight loss consultation to discuss weight history, goals, prior treatments, and health concerns
Legal Risks Under Connecticut Law The Attorney General warns that offering or advertising compounded GLP-1 drugs may constitute deceptive trade practices under CUTPA, which could lead to: Civil fines Regulatory investigations Cease and desist orders Reputational harm and patient distrust Although the letter does not accuse any specific provider of wrongdoing, it puts the industry on notice
Table 2 illustrates how the microbiome may be effected by long-term PPI use
By simultaneously activating these receptors, retatrutide optimises: Weight loss Insulin secretion Glucose metabolism Thermogenic processes Consequently, retatrutide significantly outperforms peptides that target fewer metabolic pathways